Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease

Diabetes

Volumn 62, Issue 9, 2013, Pages 3232-3240

  Teff, Karen L ^a   Rickels, Michael R ^b   Grudziak, Joanna ^a   Fuller, Carissa ^b   Nguyen, Huong Lan ^a   Rickels, Karl ^c  

^a MONELL CHEMICAL SENSES CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; FATTY ACID; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE OXIDASE; INSULIN; LEPTIN; OLANZAPINE; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; APPETITE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG TOLERABILITY; FATTY ACID BLOOD LEVEL; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; HUNGER; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIPID STORAGE; MALE; MENTAL DISEASE; METABOLISM; NORMAL HUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TEST MEAL; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; WEIGHT GAIN; CONTROLLED CLINICAL TRIAL; EATING; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; EATING; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MENTAL DISORDERS; PIPERAZINES; POSTPRANDIAL PERIOD; QUINOLONES; WEIGHT GAIN; YOUNG ADULT;

EID: 84887345283     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0430     Document Type: Article

References (48)

1. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
2. Gianfrancesco F, Pesa J, Wang RH, Nasrallah H. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. Am J Health Syst Pharm 2006;63:431-441
3. Basu A, Meltzer HY. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophr Res 2006;86:99-109
4. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother 2007;7:829-839
5. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008;105:175-187
6. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68(Suppl. 1):20-27
7. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-1773
8. Rosenheck R, Leslie D, Sernyak M. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med Care 2001;39:302-308
9. Patel JK, Buckley PF, Woolson S, et al.; CAFE Investigators. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009;111:9-16
10. Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 2007;93:90-98
11. Henderson DC, Copeland PM, Borba CP, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006;67:789-797
12. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004;65(Suppl. 18):36-46
13. Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology 2007;32:2561-2569
14. Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 2008;103:104-109
15. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
16. Ganguli R, Brar JS, Garbut R, Chang CC, Basu R. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses 2011;5:75-79
17. Wang LJ, Ree SC, Huang YS, Hsiao CC, Chen CK. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 2013;40:260-266
18. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010;35:1997-2004
19. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002;87: 2918-2923
20. Sowell M, Mukhopadhyay N, Cavazzoni P, et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyper-insulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003;88:5875-5880
21. Fountaine RJ, Taylor AE, Mancuso JP, et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring) 2010;18:1646-1651
22. Sacher J, Mossaheb N, Spindelegger C, et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008;33:1633-1641
23. Vidarsdottir S, de Leeuw van Weenen JE, Frölich M, Roelfsema F, Romijn JA, Pijl H. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab 2010;95:118-125
24. Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS ONE 2011;6:e22662
25. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neu-ropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl. 20):22-33; quiz 34-57
26. Toffolo G, Basu R, Dalla Man C, Rizza R, Cobelli C. Assessment of postprandial glucose metabolism: conventional dual-vs. triple-tracer method. Am J Physiol Endocrinol Metab 2006;291:E800-E806
27. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985;6:45-86
28. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 1984;33:486-494
29. Polonsky K, Jaspan J, Pugh W, et al. Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction. J Clin Invest 1983;72:1114-1123
30. Kim SP, Ellmerer M, Kirkman EL, Bergman RN. Beta-cell "rest" accompanies reduced first-pass hepatic insulin extraction in the insulin-resistant, fat-fed canine model. Am J Physiol Endocrinol Metab 2007;292:E1581-E1589
31. Basu R, Chandramouli V, Dicke B, Landau B, Rizza R. Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes 2005;54:1942-1948
32. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000;11:351-356
33. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994;107:1848-1855
34. Ahrén B, Holst JJ, Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care 2003;26:2860-2864
35. Teff KL, Engelman K. Oral sensory stimulation improves glucose tolerance in humans:effects on insulin, C-peptide, and glucagon. Am J Physiol 1996; 270:R1371-R1379
36. Teff KL, Townsend RR. Early phase insulin infusion and muscarinic blockade in obese and lean subjects. Am J Physiol 1999;277:R198-R208
37. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-165
38. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-613
39. Vidarsdottir S, Roelfsema F, Streefland T, Holst JJ, Rehfeld JF, Pijl H. Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. Eur J Endocrinol 2010;162:75-83
40. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35
41. Johnson DE, Yamazaki H, Ward KM, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005;54:1552-1558
42. Teff KL, Kim SF. Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. Physiol Behav 2011;104:590-598
43. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119:171-179
44. Hahn M, Chintoh A, Giacca A, et al. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Res 2011;131:90-95
45. Teff KL, Townsend RR. Prolonged mild hyperglycemia induces vagally mediated compensatory increase in C-peptide secretion in humans. J Clin Endo Metab 2004;89:5606-5613
46. Tzavara ET, Bymaster FP, Nomikos GG. The procholinergic effects of the atypical antipsychotic olanzapine are independent of muscarinic autor-eceptor inhibition. Mol Psychiatry 2006;11:619-621
47. Nauck MA. Unraveling the science of incretin biology. Eur J Intern Med 2009;20(Suppl. 2):S303-S308
48. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999;96:513-523